EPD Adoption Drives US Plaque Modification Market
According to a new report by Millennium Research Group (MRG), the US market for plaque modification, comprised of coronary atherectomy, thrombectomy, embolic protection devices (EPDs), and chronic total occlusion (CTO) devices, was valued at over $100 million in 2004 and will grow in excess of 15% through 2009.
(PRWEB) August 3, 2005 -— The presence of intravessel plaque is a significant
health concern for a growing portion of the US population. Over time,
intravessel plaque can accumulate and harden, limiting vascular blow flow and
placing an individual at an increased risk for acute myocardial infarction
(heart attack), stroke, or blood clots. Though various surgical approaches exist
to treat hardened plaque, physician and patient demand for preventative and less
invasive treatment techniques has heightened awareness and fueled growth in the
budding US plaque modification market.
According to a new report by
Millennium Research Group (MRG), the US market for plaque modification,
comprised of coronary atherectomy, thrombectomy, embolic protection devices
(EPDs), and chronic total occlusion (CTO) devices, was valued at over $100
million in 2004 and will grow in excess of 15% through 2009. Plaque modification
devices are designed for use in percutaneous coronary intervention (PCI)
procedures, of which more than 1 million were performed in the US in 2004. As
the US baby boomer generation ages and encounters an elevated risk for coronary
artery disease, the patient population for PCI procedures will continue to
increase over the foreseeable future.
With EPD penetration in PCI
procedures set to quadruple by 2009, EPDs constitute the fastest-growing segment
of the US plaque modification market. Physicians are increasingly adopting these
devices as a stroke prevention measure. In addition to clinically based
physician demand, multiple EPD product launches in 2004 and 2005, including
Boston Scientific’s FilterWire EZ and Kensey Nash’s TriActiv System, will enable
the EPD market to grow in excess of 40% over the next 5 years.
US Markets
for Plaque Modification 2005 is part of MRG’s 2005 Marketfocus series, which
offers US and European brand- and quarter-level coverage of coronary stents,
PTCA balloons, and accessory devices as well as US coverage of plaque
modification. MRG has also relaunched its Global Interventional Cardiology
series, which features in-depth analysis of IC-related markets in the US, with
forthcoming coverage of Europe, Japan, Latin America, and Asia Pacific. Global
competitive coverage includes Abbott Vascular (ABT), Boston Scientific (BSX),
Cordis (JNJ), Guidant (GDT), and Medtronic (MDT), among others.
A leading
source of competitive intelligence, MRG is now the largest provider of medical
device market research in the world. Located in Toronto, Canada, MRG covers
global markets and has pioneered reporting of numerous emerging
products.
Contact:
Derrick Navarro
416-364-7776
e-mail protected
from spam bots
# # #
Source : http://www.prweb.com/releases/2005/8/prweb266511.htm